

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Lockyer CONF. NO.: 1674
SERIAL NO.: 10/560,956 GROUP NO.: Not yet assigned
FILING DATE: December 15, 2005 EXAMINER: Not yet assigned
TITLE: METHODS FOR IDENTIFYING COMPOUNDS INTERACTING
WITH SMALL MEMBRANE-BOUND GTP-ASES

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and

- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Information Disclosure Statement
U.S. Serial No.: 10/560,956
Atty. Docket No.: MKC-008

Respectfully submitted,

Date: July 19, 2006
Reg. No. 58,312

Tel. No.: (617) 570-1657
Fax No.: (617) 523-1231

VER 9/00
LIBC/2798334.1

A handwritten signature in black ink, appearing to read "Randall D. Morin", is positioned above a horizontal line.

Randall D. Morin
Attorney for Applicants
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Goodwin Customer No. 051414

| | | | | | | | | | |
|--|---|---|-------------|---------------------------------------|------------------------|------------------|-----------------------------------|----------------------|-----------------------|
| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: MKC-008 | | | | | |
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Lockyer | | | | | |
| | | | | SERIAL NO.: 10/560,956 | | | | | |
| | | | | FILING DATE: December 15, 2005 | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | | |
| | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENG LANG (Y/N) |
| | B1 | WO 98/37196 | 08/27/1998 | PCT | | | | | Y |
| | B2 | WO 02/008245 | 01/31/2002 | PCT | | | | | Y |
| | B3 | WO 02/052272 | 07/04/2002 | PCT | | | | | Y |
| OTHER ART, JOURNAL ARTICLES, ETC. | | | | | | | | | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | | | | | | | |
| | C1 | Barbacid, M., "ras GENES" (1987) <u>Ann. Rev. Biochem.</u> 56: 779-827. | | | | | | | |
| | C2 | Bos, J., "ras Oncogenes in Human Cancer: A Review" (1989) <u>Cancer Research</u> 49(17): 4682-4689. | | | | | | | |
| | C3 | Campbell, S., <i>et al.</i> , "Increasing complexity of Ras signaling" (1988) <u>Oncogene</u> 17(11): 1395-1413. | | | | | | | |
| | C4 | Chiu, V. <i>et al.</i> , "Ras signalling on the endoplasmic reticulum and the Golgi" (2002) <u>Nature Cell Biology</u> 4: 343-350. | | | | | | | |
| | C5 | Cichowski, K. <i>et al.</i> , "NF1 Tumor Suppressor Gene Function: Narrowing the GAP" (2001) <u>Cell</u> 104(4): 593-604. | | | | | | | |
| | C6 | Cullen, P. <i>et al.</i> , "Integration of Calcium and Ras Signaling" (2002) <u>Nature Reviews Molecular Cell Biology</u> 3(5): 339-348. | | | | | | | |
| | C7 | Dorn, G. <i>et al.</i> , "Intracellular Transport Mechanisms of Signal Transducers" (2002) <u>Annu. Rev. Physiol.</u> 64:407-29. | | | | | | | |
| | C8 | Dorn, G. <i>et al.</i> , "Sustained <i>in vivo</i> cardiac protection by a rationally designed peptide that causes ϵ protein kinase C translocation" (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96(22): 12798-12803. | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| | | |
|-----------------------------------|--|---|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: MKC-008 |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Lockyer |
| | | SERIAL NO.: 10/560,956 |
| | | FILING DATE: December 15, 2005 |
| OTHER ART, JOURNAL ARTICLES, ETC. | | |
| EXA M. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | |
| | C9 | Gibbs, J. <i>et al.</i> , "Modulation of Guanine Nucleotides Bound to Ras in NIH3T3 Cells by Oncogenes, Growth Factors, and the GTPase Activating Protein (GAP)" (1990) <u>Jrl. of Biol. Chem.</u> 265(33): 20437-20442. |
| | C10 | Hoa, M. <i>et al.</i> , "Amplification of Wild-Type K-ras Promotes Growth of Head and Neck Squamous Cell Carcinoma" (2002) <u>Cancer Research</u> 62(24): 7154-7156. |
| | C11 | Kato-Stankiewicz, J. <i>et al.</i> , "Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells" (2002) <u>Proc. Natl. Acad. Sci. USA</u> 99:14398-14403. |
| | C12 | Kim, S.H. <i>et al.</i> , "E-cadherin -mediated Cell-Cell Attachment Activates Cdc42" (2000) <u>Jrl. of Biol. Chem.</u> 275: 36999-37005. |
| | C13 | Lockyer, P. <i>et al.</i> , "CAPRI regulates Ca ²⁺ -dependent inactivation of the Ras-MAPK pathway" (2001) <u>Current Biology</u> 11(12): 981-986. |
| | C14 | Nori M. <i>et al.</i> , "Inhibition of v-src-Induced Transformation by a GTPase-Activating Protein" (1991) <u>Molecular and Cellular Biology</u> 11(5): 2812-2818. |
| | C15 | Rodriquez, M. <i>et al.</i> , "RACK1, a Protein Kinase C Anchoring Protein, Coordinates the Binding of Activated Protein Kinase C and Select Pleckstrin Homology Domains in Vitro" (1999) <u>Biochemistry</u> 38(42): 13787-13794. |
| | C16 | Ron, D. <i>et al.</i> , "An autoregulatory region in protein kinase C: The pseudoanchoring site" (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92(2): 492-496. |
| | C17 | Ron, D. <i>et al.</i> , "Cloning of an intracellular receptor for protein kinase C: A homolog of the β subunit of G proteins" (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91(3): 839-843. |
| | C18 | Ron, D. <i>et al.</i> , "C2 Region-derived Peptides Inhibit Translocation and Function of β Protein Kinase C <i>in Vivo</i> " (1995) <u>Jrl. of Biol. Chem.</u> 270(41): 24180-24187. |
| | C19 | Smith, M. <i>et al.</i> , "Requirement for c-ras proteins during viral oncogene transformation" (1986) <u>Nature</u> 320(6062): 540-543. |
| | C20 | Srinivasan, S., "Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P ₃ and polarity during neutrophil chemotaxis" (2003) <u>Jrl. of Cell Biology</u> 160: 375-385. |
| | C21 | International Search Report for International Application No. PCT/GB2004/001765, completed September 10, 2004, 1 page. |
| | C22 | Great Britain Search Report under Section 17 for Application No.: GB 0314980.4, completed October 13, 2003, 1 page. |
| EXAMINER | | DATE CONSIDERED |